London, UK (PRWEB) June 30, 2014
What are the major big pharma companies involved in the antibody market space? What are the prevailing trends in antibody dealmaking in the overall biopharma industry since 2007? What does the company’s recent antibody dealmaking activity look like? What is actually granted by the antibody dealmaking agreement to a partner company? What are the main terms included in a partnering agreement? What does the payment structure of the deal look like? What are the key aspects of antibody partnering? How to assess a prospective partner’s flexibility on a wide range of aspects? How are the main terms of the antibody partnering agreement defined? How to determine under what terms a prospective partner agrees to a partnering relationship? Which of the partners is responsible for commercialization, development, manufacture and supply? How are arising disputes to be resolved? What is actually granted by the agreement to the partner company? What are the key conditions for the antibody deal termination? Which jurisdiction does the company insist upon for agreement law? Which boilerplate clauses differ from deal type to deal type or partner to partner?
Answers to these and many other questions can be found in the new research study “Antibody Partnering Terms and Agreements” worked out by CurrentPartnering and now available at MarketPublishers.com.
Title: Antibody Partnering Terms and Agreements
Published: June, 2014
Price: US$ 2,995.00
The new report provides a wealthy pack of important data on the antibody partnering deals and agreements entered into by the dominant companies playing in the worldwide healthcare sector. Moreover, the study throws light on the major trends in antibody partnering deals, presents extensive analysis of the products in different stages of development, gives clear examples of partnering contact documents, and also offers a valuable ranking of top antibody deals by value. A detailed investigation of how and why different enterprises enter partnering deals, profound insights into the partnering negotiation processes and thorough discussions of the essential aspects of the antibody partnering deals are available in the report.
Reasons to Buy: